Search

Displaying results 7451 - 7460 of 7657 in total
  1. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    TM5614 is a novel, orally active, plasminogen activator inhibitor 1 (PAI-1) inhibitor[A228788,A228793,]. PAI-1 is a marker of obesity, type 2 diabetes, and metabolic syndrome , and current studies are exploring downstream effects of its ...

  2. Drug

    VLTS-589

    go.drugbank.com/drugs/DB05430
    Investigational

    VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.

  3. Drug

    Nadifloxacin

    go.drugbank.com/drugs/DB12447
    Investigational

    Nadifloxacin has been used in trials studying the treatment of Acne Vulgaris.

  4. Drug

    Tin protoporphyrin IX

    go.drugbank.com/drugs/DB16449
    Investigational

    Synonyms: Dihydrogen (OC-6-13)-dichloro[7,12-diethenyl-3,8,13,17-tetramethylporphyrin-2,18-dipropionato(4-)-N<sup>21</sup>,N<sup>22</sup>,N<sup>23</sup>,N<sup>24</sup>]stannate(2-)-
  5. Drug

    Polyinosinic-polycytidylic acid

    go.drugbank.com/drugs/DB16467
    Investigational

    Synonyms: BO-112
  6. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236 (completed for type 1 dia...

  7. Drug

    Carrimycin

    go.drugbank.com/drugs/DB16476
    Investigational

  8. Drug

    ISIS 325568

    go.drugbank.com/drugs/DB06099
    Investigational

    ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR). It was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping...

  9. Drug

    VGV-1

    go.drugbank.com/drugs/DB05328
    Experimental

    VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.

  10. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). The investigational drug was under investigation in clinical trial NCT00473...